Company Filing History:
2 out of 53 
2 out of 19 
2 out of 2 Years Active: 2010-2012
Title: Michael Christiansen: Innovator in Abnormal Cell Function Markers
Introduction
Michael Christiansen is a notable inventor based in Holte, Denmark. He has made significant contributions to the field of medical diagnostics, particularly in identifying markers for abnormal cell function. With two patents to his name, his work has the potential to impact clinical outcomes in various medical conditions.
Latest Patents
One of Christiansen's latest patents is titled "ADAM12, a novel marker for abnormal cell function." This invention provides a method, an assay, and a kit for indicating abnormal cell function. The research revealed that changes in serum ADAM12 concentration can serve as a prognostic tool to predict clinical outcomes, complications, and mortality associated with abnormal cell function. The invention describes ADAM12 as a general marker for abnormal cell function and demonstrates its importance as an indicator of fetal chromosomal diseases and placental function. Specifically, ADAM12 is a reliable marker for conditions such as Down's syndrome, trisomy 18, preeclampsia, and Turner syndrome during both the first and second trimesters. The inventors developed an enzyme-linked immunosorbent assay (ELISA) and a time-resolved immunofluorometric assay for quantifying ADAM12 in serum. The application illustrates the variation of ADAM12 levels in relation to fetal abnormalities and adverse pregnancy outcomes, correlated with gestational age when compared to normal controls. The invention aims to improve existing marker tests by reducing the false positive rate.
Career Highlights
Michael Christiansen has worked with reputable organizations, including Statens Serum Institut and Københavns Universitet. His experience in these institutions has contributed to his expertise in medical research and diagnostics.
Collaborations
Some of his notable coworkers include Ulla M Wewer and Jennie Laigaard. Their collaboration has likely enhanced the research and development of innovative diagnostic tools.
Conclusion
Michael Christiansen's work in developing ADAM12 as a marker for abnormal cell function showcases his innovative spirit and dedication to improving medical diagnostics. His contributions have the potential to significantly influence clinical practices and patient outcomes.